Clinical Trial Update: A Study to testABI-009 in Patients With Metastatic, Unresectable, Low or Intermediate Grade Neuroendocrine Tumors of the Lung or Gastroenteropancreatic System [Phase 2]

View source ↗

Summary

Phase 2 study of ABI-009 in metastatic, unresectable neuroendocrine tumors of the lung or gastrointestinal system was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Tumors

Drugs mentioned

• ABI-009

Snippet

Sponsor: Robert Ramirez | Conditions: Neuroendocrine Tumors | Phase 2 | Status: TERMINATED | Results posted: 2021-06-10